Last reviewed · How we verify

NCT07017322

Non-invasive Cranial Electrical Stimulation for Mealtime Anxiety in Adults With Eating Disorders

Recruiting now NA Last updated 12 June 2025
What this trial tests

NA trial testing Alpha-Stim AID in Eating Disorders in 30 participants. Currently enrolling.

Timeline
3 June 2025
Primary endpoint
1 November 2027
1 November 2027

Quick facts

Lead sponsorRogers Behavioral Health
PhaseNA
StatusRecruiting now
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposetreatment
Enrollment30
Start date3 June 2025
Primary completion1 November 2027
Estimated completion1 November 2027
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

Rogers Behavioral Health

Who can join

Adults 18 to 30, any sex, with Eating Disorders or Anxiety. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The study is to evaluate the feasibility of using a non-invasive brain stimulation device in a sample of inpatients with eating disorders (ED). The study will help researchers evaluate whether their device protocol is practical for eating disorder inpatients as a way to manage eating disorder and anxiety symptoms. A secondary aim of the study is to evaluate preliminary effectiveness of the protocol for reducing pre-meal anxiety during the treatment, and explore effects on eating disorder symptoms over the course of the inpatient admission.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Eating Disorders

Currently open trials in the same condition.

Other Rogers Behavioral Health trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07017322.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing